Fundraising Fox

SCI Ventures

Venture capital

London · Seed–Series B · 18 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

SCI Ventures is a dedicated venture fund focused on accelerating cures and treatments for paralysis, starting with spinal-cord injury and related markets. Backed by leading paralysis research foundations and clinical centers, the fund brings together investors, entrepreneurs, clinicians and neuroscientists. It invests globally in early-stage companies — typically Seed through Series B — that are built around rigorous, innovative scientific advancements with the greatest potential to impact people living with spinal cord injury. Its aim is to move therapies from the lab to the clinic faster, catalyzing both symptomatic and curative treatments for neurological conditions.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Series B
HQ
London, GB
Instruments
Equity
Founded
2024
Last 12 months
1 investment
AUM
$27M
Tracked investments
12

Team · 18 people

from the firm's website & public directories
Ian Curtis· Board Member, ISRT and Reeve Foundation

Chairman of HPC plc and a former PwC partner; board member for ISRT and the Reeve Foundation.

Tom Londres· Board Member, Reeve Foundationin

CEO of Metro Commercial, Inc. and a board member of the Reeve Foundation.

Murray Blackmore· Scientific Advisory Council Memberin

Professor at Marquette University and a leader in nerve regeneration and genetic control.

Peter Luckeneder· Board Memberin

Global CFO of Wings for Life.

Rob Brownstone· Scientific Advisory Council Memberin

Professor of Neurosurgery at Brain Research UK and Head of the Division of Neurosurgery at UCL.

Founder mafia

3 people who came through SCI Ventures went on to found or lead other companies.

What they invest in

from 4 of 12 portfolio companies

Biotech ×3Healthtech ×3Deep Tech ×2AI & Machine Learning ×1Digital Health ×1Medical Devices ×1

HQs:United States×2United Kingdom×1

Investments · 12 tracked

founders shown can be your intro path

By year:2025 · 12024 · 12 dated

NervGen Pharmanervgen.comin𝕏NASDAQ: NGEN

NervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair.

BiotechDeep TechHealthtechMedical Devices

Dr. Jerry SilverHarold Punnett(Co-founder)inJerry Silver(Co-founder)William Adams(Executive Officer)Paul Brennan(Director, Executive Officer)Daniel Mikol(Executive Officer)

Co-investorsCWRU Technology Ventures

Augmental
Axonis
Axonis Therapeuticsaxonis.usinOct 2024

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)

Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+7 more

Craighospitalcraighospital.org
Cyllene Therapeutics

Developing targeted gene therapy platform for specific neuronal populations, with initial focus on neurogenic detrusor overactivity in spinal cord injury and neurodegenerative diseases.

Eg
Healxhealx.ioin𝕏

Healx is an AI-powered biotech company that discovers and develops treatments for rare diseases.

AI & Machine LearningBiotechDigital HealthHealthtechCambridge, GB

Tim Guilliams(Co-founder & CEO)in

Co-investorsAmadeus Capital PartnersBalderton CapitalCambridge Angels groupIntel Capital

Onward

Leader in spinal cord stimulation technology using targeted programmed stimulation to restore movement and function, with first FDA approval expected in 2024.

Onward Medical
Precision NeuroscienceinNov 2025

HealthtechNew York, US

Benjamin Rapoport(President, Chief Science Officer)Michael Mager(Chief Executive Officer)Craig Mermel(President and Chief Product Officer)MIchael Kaswan(Chief Financial Officer)

BoardEric M. Attias(Director)Howard Morgan(Director)in

Co-investorsAlumni VenturesB Capital GroupBasecamp FundForepont Capital PartnersSteadview Capital

Sania Therapeutics

Exits · 1

IPOs and acquisitions across the tracked portfolio

NervGen PharmaNASDAQ: NGEN

Portfolio news

latest coverage across their companies
Trysignalbase

Precision Neuroscience · trysignalbase.com · Mar 9, 2026

Frequently asked questions

How many investments has SCI Ventures made?
SCI Ventures has 13 tracked investments, including 2 dated in the last 24 months.
What stage does SCI Ventures invest at?
SCI Ventures invests at the Seed, Series A, Series B stages.
What sectors does SCI Ventures focus on?
SCI Ventures focuses on Biotech, Deep Tech, Healthtech, Impact & Social Good, Medical Devices.
Where is SCI Ventures located?
SCI Ventures is headquartered in London, GB.
Who does SCI Ventures co-invest with?
SCI Ventures most often shares deals with Amadeus Capital Partners, B Capital Group, Balderton Capital, among 28 tracked co-investors.

Images

SCI Ventures photo

Similar investors

Featured in lists